 |
市場調查報告書
商品編碼
1673034
急性腎損傷治療市場按類型、療法、分銷管道和地區分類Acute Kidney Injury Treatment Market, By Type, By Treatment, By Distribution Channel, By Geography |
||||||
2025 年全球急性腎損傷治療市場規模估計為 19.6 億美元，預計到 2032 年將達到 34.3 億美元，2025 年至 2032 年的複合年成長率為 8.3%。
| 報告範圍 | 報告詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025 年市場規模 | 19.6億美元 |
| 效能資料 | 2020-2024 | 預測期 | 2025-2032 |
| 預測期：2025 年至 2032 年複合年成長率 | 8.30％ | 2032 年金額預測 | 34.3億美元 |
急性腎損傷 (AKI) 是指因腎功能突然下降而導致腎臟正常清除的廢物在血液中積聚的情況。這是一種嚴重的疾病，需要立即就醫，以防止進一步的腎臟損傷和腎衰竭。全球急性腎損傷治療市場的成長是由糖尿病和高血壓等合併症盛行率的上升所推動的，這增加了 AKI 的風險。此外，新藥物和治療方法的開發正在擴大患者的治療選擇。然而，公眾和醫療保健提供者對 AKI 缺乏認知可能會阻礙市場的成長。
市場動態
全球急性腎損傷治療市場的成長是由老年人口的增加所推動的，由於隨著老齡化的腎功能下降，老年人更容易患上急性腎損傷 (AKI)。根據聯合國預測，到 2050 年，65 歲及以上人口數量將達到 15 億以上。由於生活方式的改變導致慢性腎臟病盛行率的增加也將推動市場成長。然而，腎臟替代療法的高成本可能會限制其廣泛應用。缺乏對 AKI 早期診斷的認知可能會阻礙市場的成長。用於早期檢測 AKI 的生物標記的開發為市場開發商擴展該領域的業務提供了機會。即時監測液體狀態可實現即時客製化護理。數位健康解決方案也有助於遠端患者管理。
研究的主要特點
本報告對全球急性腎損傷治療市場進行了詳細分析，並提供了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%），假設 2024 年為基準年。
它還強調了各個領域的潛在商機並說明了該市場的有吸引力的投資提案矩陣。
它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
全球急性腎損傷治療市場的主要企業是根據公司亮點、產品系列、關鍵亮點、業績和策略等參數進行介紹的。
研究涉及的主要企業包括 Fresenius Medical Care AG & Co.KGaA、百特 (Baxter)、Angion Biomedica Corp、AM-Pharma 和 Quark Pharmaceuticals, Inc.
本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球急性腎損傷治療市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過全球急性腎損傷治療市場分析中使用的各種策略矩陣來促進決策。
目錄
第1章 調查目的與前提條件
- 研究目標
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
第3章市場動態、法規與趨勢分析
- 市場動態
- 影響分析
- 監管情景
- 產品發布/核准
- PEST分析
- 波特分析
- 併購情景
4. 2020 年至 2032 年全球急性腎損傷治療市場（按類型分類）（十億美元）
- 介紹
- 腎前性急性腎損傷
- 腎內源性急性腎損傷
- 腎後性急性腎損傷
5. 2020 年至 2032 年全球急性腎損傷治療市場（按療法分類）（十億美元）
- 介紹
- 治療
- 藥物
6. 2020-2032 年全球急性腎損傷治療市場按通路分類（十億美元）
- 介紹
- 醫院藥房
- 零售藥局
- 網路藥局
7. 2020 年至 2032 年全球急性腎損傷治療市場（按地區分類）（十億美元）
- 介紹
- 北美洲
- 拉丁美洲
- 歐洲
- 亞太地區
- 中東
- 非洲
第8章 競爭格局
- Angion Biomedica Corp.
- AM-Pharma
- Quark Pharmaceuticals, Inc.
- Baxter International, Inc.
- Fresenius Medical Care AG & Co. KGaA
- Braun Melsungen AG
- Asahi Kasei Medical Co., Ltd.
- LG Chem
- Kringle Pharma, Inc.
- AstraZeneca
- Amgen Inc.
- Gilead Sciences
- Roche
- Merck & Co., Inc.
- Pfizer Inc.
- Sanofi
- Bristol-Myers Squibb
- Eli Lilly and Company
- Novartis AG
- AbbVie Inc.
第 9 章分析師建議
- 興衰
- 一致的機會地圖
第10章參考文獻與調查方法
- 參考
- 調查方法
- 關於出版商
Global Acute Kidney Injury Treatment Market is estimated to be valued at USD 1.96 Bn in 2025 and is expected to reach USD 3.43 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 1.96 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.30% | 2032 Value Projection: | USD 3.43 Bn |
Acute kidney injury (AKI) refers to an abrupt loss of kidney function, resulting in the build-up of waste products in the blood that would normally be removed by the kidneys. It is a serious condition that requires prompt medical care to prevent further kidney damage and failure. Global acute kidney injury treatment market growth is driven by rising prevalence of comorbid conditions such as diabetes and hypertension that increases the risk of AKI. Furthermore, development of novel drugs and treatment approaches has expanded therapeutic options for patients. However, lack of awareness among people and healthcare providers about AKI can hamper the market growth.
Market Dynamics:
Global acute kidney injury treatment market growth is driven by rising geriatric population who are more susceptible to AKI due to age-related decline in kidney function. According to the United Nations, the number of people aged 65 years and above is projected to reach over 1.5 billion by 2050. Growing prevalence of chronic kidney diseases due to lifestyle changes can also drive the market growth. However, high costs associated with renal replacement therapies can limit widespread adoption. Lack of awareness about early diagnosis of AKI can hamper the market growth. Development of biomarkers for early detection of AKI presents lucrative opportunities for market players to expand their offerings in this area. Real-time monitoring of fluid status offers real-time customized care. Digital health solutions can also aid remote patient management.
Key features of the study:
This report provides in-depth analysis of the global acute kidney injury treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global acute kidney injury treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Fresenius Medical Care AG & Co. KGaA, Baxter, Angion Biomedica Corp, AM-Pharma, and Quark Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global acute kidney injury treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute kidney injury treatment market
Detailed Segmentation-
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Prerenal Acute Kidney Injury
- Intrinsic Renal Acute Kidney Injury
- Postrenal Acute Kidney Injury
- Treatment Insights (Revenue, USD Bn, 2020 - 2032)
- Therapy
- Drugs
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Angion Biomedica Corp.
- AM-Pharma
- Quark Pharmaceuticals, Inc.
- Baxter International, Inc.
- Fresenius Medical Care AG & Co. KGaA
- Braun Melsungen AG
- Asahi Kasei Medical Co., Ltd.
- LG Chem
- Kringle Pharma, Inc.
- AstraZeneca
- Amgen Inc.
- Gilead Sciences
- Roche
- Merck & Co., Inc.
- Pfizer Inc.
- Sanofi
- Bristol-Myers Squibb
- Eli Lilly and Company
- Novartis AG
- AbbVie Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Acute Kidney Injury Treatment Market, By Type
- Global Acute Kidney Injury Treatment Market, By Treatment
- Global Acute Kidney Injury Treatment Market, By Distribution Channel
- Global Acute Kidney Injury Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Acute Kidney Injury Treatment Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Prerenal Acute Kidney Injury
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intrinsic Renal Acute Kidney Injury
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Postrenal Acute Kidney Injury
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Acute Kidney Injury Treatment Market, By Treatment, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Acute Kidney Injury Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Acute Kidney Injury Treatment Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Angion Biomedica Corp.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AM-Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Quark Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Baxter International, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Fresenius Medical Care AG & Co. KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Braun Melsungen AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Asahi Kasei Medical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- LG Chem
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Kringle Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Roche
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Pfizer Inc.
- Sanofi
- Bristol-Myers Squibb
- Eli Lilly and Company
- Novartis AG
- AbbVie Inc.
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
